Drug Patents owned by Emd Serono Inc

1. Drug name - MAVENCLAD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7888328 EMD SERONO INC Oral formulations of cladribine Apr, 2024

(1 year, 6 months from now)

US8785415 EMD SERONO INC Oral formulations of cladribine Apr, 2024

(1 year, 6 months from now)

US8377903 EMD SERONO INC Cladribine regimen for treating multiple sclerosis May, 2026

(3 years from now)

US7713947 EMD SERONO INC Cladribine regimen for treating multiple sclerosis Oct, 2026

(4 years from now)

Drugs and Companies using CLADRIBINE ingredient

Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusion complex, cladribine/cyclodextrin 1:10-1:16 w/w; Treatment of ms with an admixture of (a) an amorphous inclusion complex of cladribine (2cda) and cyclodextrin and (b) amorphous free 2cda and cyclodextrin as a non-inclusion complex, formulated as a solid oral form, w/o sign. amounts of cryst. 2cda; Treating rrms or spms with oral cladribine: (i) 2-4 months induction with 1.7 mg/kg - 3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) 2-4 months maintenance with about 1.7 mg/kg cladribine; (iv) cladribine-free period; Treating ms with oral cladribine acc. to the steps (i) induction period with about 1.7 mg/kg-3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) maintenance period with about 1.7 mg/kg cladribine; (iv) cladribine-free period

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription

2. Drug name - TEPMETKO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8921357 EMD SERONO INC Pyridazinone derivatives
May, 2028

(5 years from now)

US8329692 EMD SERONO INC Pyrimidinyl pyridazinone derivatives
Oct, 2029

(7 years from now)

US8580781 EMD SERONO INC Pyridazinone derivatives
Mar, 2030

(7 years from now)

CN101687857B EMD SERONO INC Pyridazinone Derivates
Apr, 2028

(5 years from now)

CN101743241B EMD SERONO INC Pyridazinone Derivatives
Apr, 2028

(5 years from now)

CN101687857A EMD SERONO INC Pyrimidinyl Pyridazinone Derivative
Apr, 2028

(5 years from now)

CN101743241A EMD SERONO INC Pyridazinone Derivates
Apr, 2028

(5 years from now)

IN281477B EMD SERONO INC Pyridazinone Derivatives
Apr, 2028

(5 years from now)

IN201000482P2 EMD SERONO INC Pyridazinone Derivatives
Apr, 2028

(5 years from now)

IN273292B EMD SERONO INC Pyrimidinyl-Pyridazinone Derivatives
Jul, 2028

(5 years from now)

IN201000486P2 EMD SERONO INC Pyrimidinyl-Pyridazinone Derivates
Jul, 2028

(5 years from now)

EP2754660A1 EMD SERONO INC Pyridazinone Derivatives
Apr, 2028

(5 years from now)

EP2754660B1 EMD SERONO INC Pyridazinone Derivatives
Apr, 2028

(5 years from now)

EP2164843A1 EMD SERONO INC Pyridazinone Derivates
Apr, 2028

(5 years from now)

EP2164843B1 EMD SERONO INC Pyridazinone Derivates
Apr, 2028

(5 years from now)

EP2164844A1 EMD SERONO INC Pyrimidinyl Pyridazinone Derivates
Jul, 2028

(5 years from now)

EP2164844B1 EMD SERONO INC Pyrimidinyl Pyridazinone Derivates
Jul, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284300 EMD SERONO INC Pyridazinone derivatives Apr, 2028

(5 years from now)

US9403799 EMD SERONO INC Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase Jul, 2028

(5 years from now)

US9062029 EMD SERONO INC Pyrimidinyl pyridazinone derivatives Jul, 2028

(5 years from now)

US8658643 EMD SERONO INC Pyrimidinyl pyridazinone derivatives Jul, 2028

(5 years from now)

US8927540 EMD SERONO INC Pyridazinone derivatives Jul, 2028

(5 years from now)

Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient

Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by administering an effective amount of tepotinib; Treating a solid tumor, including lung cancer, having a met kinase alteration(s) by administering an effective amount of tepotinib

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 225MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.